Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UNITED STATES: FDA Approves Hepatitis B Viral DNA Test
The first hepatitis B virus (HBV) nucleic acid test to measure the amount of viral DNA in a patient's blood has won Food and Drug Administration approval. 'The COBAS TaqMan HBV Test extracts and then amplifies sections of viral DNA from human plasma or

Toll rises to 121 in Uganda hepatitis epidemic
A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday. A diagram showing the hepatitis C virus © AFP/File KAMPALA (AFP) - The outbreak has mainly affected

Roche Molecular Diagnostics Wins FDA OK for Hepatitis B Test
A hepatitis B viral load test, developed by Roche Molecular Diagnostics in Pleasanton, was approved by the Food and Drug Administration.

UPDATES AND COMMENTARY RSS Feed

HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...

Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...



Intraobserver and Interobserver Variations in Liver Biopsy

Interpretation in Patients with Chronic Hepatitis C


Authors: The French METAVIR Cooperative Study Group.
Journal: Hepatology 1994 Jul;20(1 Pt 1):15-20

Liver biopsy is used as the "gold standard" for the assessment of the stage and degree of activity in chronic Hepatitis C and is of major importance in evaluating the effects of treatment. Because numerous therapeutic trials are undertaken with histological control, the reproducibility of liver biopsy interpretation appears essential.
Therefore the aim of this study was to estimate intraobserver and interobserver variations in the assessment of features, classification, and numerical scoring of chronic viral Hepatitis C among 10 pathologists specializing in liver diseases. These pathologists independently reviewed 30 liver biopsy specimens of viral Hepatitis C and completed a histological form for each of the specimens. Five pairs of pathologists then were randomly designated. They independently reviewed the biopsy specimens and filled out a new coding form. The interobserver variation was calculated for each item among the 10 individuals and then among the five pairs with the intraclass correlation coefficient or kappa statistics. Five features showed an almost perfect or a substantial degree of  concordance among the 10 observers (i.e., cirrhosis, fibrosis, fibrosis grading of Knodell index, steatosis, portal lymphoid aggregates). The 17 other indicators showed a weaker concordance with, for instance, a moderate degree of concordance for piecemeal necrosis, disease activity, Knodell index, a fair degree of concordance for lobular necrosis, and only a slight degree of concordance for six items. Five items had a higher concordance when viewed by a pair of pathologists than when studied by only one pathologist (i.e., steatosis, periportal necrosis grading of Knodell index, lobular necrosis grading of Knodell index, centrilobular fibrosis, and ductular proliferation).

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 08 Sep 2008